- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01782469
Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population
July 2, 2015 updated by: AbbVie (prior sponsor, Abbott)
A Prospective, Multi-center Study in Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population
This Post-Marketing Observational Study (PMOS) was conducted to assess the effectiveness of adalimumab on reducing synovitis (inflammation of the synovial membrane, which lines movable synovial joints, such as shoulders, elbows, wrists, knees, and hips) in adult participants with Rheumatoid Arthritis (RA) in Egypt.
B-mode ultrasonography data was collected from participants receiving adalimumab treatment who had not been treated with any other anti-tumor necrosis factor (anti-TNF) therapy in the past.
Study Overview
Status
Terminated
Conditions
Detailed Description
This study was a prospective, observational, single arm, multicenter study.
Participants were treated with adalimumab in accordance with usual clinical care practices and local marketing authorization requirements.
A total of 5 visits were planned: Baseline (Visit 1), Visits 2, 3, 4 and 5 (Week 13).
The time interval between the baseline visit and the second visit was approximately 2-3 weeks, with a window of one week.
Additional study objectives were to investigate the rate of RA progression via changes in the B-mode ultrasonography assessment score over time as well as changes in the number of joints with erosion over time.
The study was terminated due to low enrollment.
Study Type
Observational
Enrollment (Actual)
16
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Private clinics
Description
Inclusion Criteria:
A patient will be enrolled in this study if he/she fulfills ALL of the following criteria:
- Male or Female patients ≥ 18 years of age with diagnosis of RA
- Patient is eligible to start adalimumab therapy according to the local product label and prescription guidelines
- Patient is naïve to all biologics e.g. anti-cluster of differentiation 4 (anti-CD4) and anti-TNF treatments at the start of the study
- Patient has no history of inflammatory arthritis other than rheumatoid arthritis
- Patient has no history of lymphoma or leukemia or other malignancies
- Has negative result of tuberculosis (TB) screening test or is receiving TB prophylaxis as per local guidelines, Provided written Authorization to the investigator to use and/or disclose personal and/or health data, or Informed Consent if requested by the Local Regulations
Exclusion Criteria:
- Patients that are not diagnosed with rheumatoid arthritis as judged by the American College of Rheumatology criteria
- Patient is currently diagnosed with any condition other than rheumatoid arthritis that may affect radiography progression
- Susceptibility to infections including TB, as judged by the investigator
- Patient is carrier of Hepatitis B virus
- Patient is a pregnant or lactating female at the time of screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Rheumatoid Arthritis (RA) participants
Male or female participants at least 18 years of age with diagnosis of RA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in Synovitis Measured by B-modal Ultrasonography Assessment Score After 13 Weeks of Treatment With Adalimumab.
Time Frame: Baseline (Visit 1) to 13 weeks
|
Synovitis was scored on a scale of 0 to 3 (0=none, 1=minor, 2=moderate, and 3=major presence).
The sum of the scores of all 12 joints (elbow, wrist, second metacarpal (MCP), third MCP, knee and ankle) on both left and right sides is the ultrasonography assessment score, with a score range of 0-36.
|
Baseline (Visit 1) to 13 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Percent Reduction in Ultrasonography Assessment Score
Time Frame: Baseline (Visit 1) to 13 weeks
|
Synovitis was scored on a scale of 0 to 3 (0=none, 1=minor, 2=moderate, and 3=major presence).
The sum of the scores of all 12 joints (elbow, wrist, second metacarpal (MCP), third MCP, knee and ankle on both left and right sides) is the ultrasonography assessment score, with a score range of 0-36.
|
Baseline (Visit 1) to 13 weeks
|
Mean Number of Joints With Detected Erosions
Time Frame: Baseline (Visit 1) to 13 weeks
|
A total of 12 joints (elbow, wrist, second metacarpal (MCP), third MCP, knee and ankle on both left and right sides) were assessed by ultrasonography at each study visit and the number of joints with erosion (wearing away) was documented.
|
Baseline (Visit 1) to 13 weeks
|
Percentage of Participants Who Achieved ≥ 20% Improvement in Both Tender Joint Count (TJC) and Swollen Joint Count (SJC)
Time Frame: Baseline (Visit 1) to 13 weeks
|
The American College of Rheumatology TJC and SJC was administered at each study visit.
Participants were evaluated for tenderness and pain in 66 different joints when in motion (TJC), and 68 different joints were evaluated for swelling (SJC).
|
Baseline (Visit 1) to 13 weeks
|
Mean Change in Health Assessment Questionnaire (HAQ) Score
Time Frame: Baseline (Visit 1) to 13 weeks
|
The Health Assessment Questionnaire - Disability Index (HAQ-DI) is a participant-reported questionnaire specific for rheumatoid arthritis.
It consists of 20 questions referring to eight domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities.
Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3).
Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where zero represents no disability and three very severe, high-dependency disability.
The minimal clinically important difference (MCID) defined for the HAQ-DI is ≥0.22.
HAQ remission indicating normal physical function is defined by HAQ-DI < 0.5.
Negative mean changes from Baseline in the overall score indicate improvement.
Due to an error, HAQ data was not collected at 13 weeks.
|
Baseline (Visit 1) to 13 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Iman Ibrahim, AbbVie
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2012
Primary Completion (Actual)
July 1, 2014
Study Completion (Actual)
July 1, 2014
Study Registration Dates
First Submitted
January 31, 2013
First Submitted That Met QC Criteria
January 31, 2013
First Posted (Estimate)
February 4, 2013
Study Record Updates
Last Update Posted (Estimate)
July 30, 2015
Last Update Submitted That Met QC Criteria
July 2, 2015
Last Verified
July 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- P13-708
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia